ProfoundBio US Co.

AbbVie Files Trade Secret Lawsuit Against Genmab Over ADC Technology in Cancer Drug Development

2 months ago

• AbbVie has filed a lawsuit against Genmab and ProfoundBio alleging misappropriation of trade secrets related to disaccharide technology in antibody-drug conjugates, which Genmab categorically refutes. • The dispute centers on rinatabart sesutecan (Rina-S), a Phase 3 FRα-targeted ADC for ovarian cancer that Genmab claims could address a broader patient population than AbbVie's Elahere regardless of FRα expression. • Despite the litigation, Genmab confirms its collaboration with AbbVie on epcoritamab will continue unaffected, with both companies maintaining their commitment to the drug's development and commercialization.